BR112014019034A8 - Método para tratamento de câncer - Google Patents

Método para tratamento de câncer

Info

Publication number
BR112014019034A8
BR112014019034A8 BR112014019034A BR112014019034A BR112014019034A8 BR 112014019034 A8 BR112014019034 A8 BR 112014019034A8 BR 112014019034 A BR112014019034 A BR 112014019034A BR 112014019034 A BR112014019034 A BR 112014019034A BR 112014019034 A8 BR112014019034 A8 BR 112014019034A8
Authority
BR
Brazil
Prior art keywords
treatment
cancer
her2
lapatinib
trastuzumab
Prior art date
Application number
BR112014019034A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112014019034A2 (enExample
Inventor
F Spraggs Colin
Original Assignee
Smithkline Beecham Cork Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Cork Ltd filed Critical Smithkline Beecham Cork Ltd
Publication of BR112014019034A2 publication Critical patent/BR112014019034A2/pt
Publication of BR112014019034A8 publication Critical patent/BR112014019034A8/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/118Prognosis of disease development
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BR112014019034A 2012-01-31 2013-01-31 Método para tratamento de câncer BR112014019034A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261592893P 2012-01-31 2012-01-31
US201261654733P 2012-06-01 2012-06-01
PCT/EP2013/051865 WO2013113796A1 (en) 2012-01-31 2013-01-31 Method of treating cancer

Publications (2)

Publication Number Publication Date
BR112014019034A2 BR112014019034A2 (enExample) 2017-06-20
BR112014019034A8 true BR112014019034A8 (pt) 2017-07-11

Family

ID=47714037

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014019034A BR112014019034A8 (pt) 2012-01-31 2013-01-31 Método para tratamento de câncer

Country Status (11)

Country Link
US (1) US20150023953A1 (enExample)
EP (2) EP2809805A1 (enExample)
JP (1) JP2015506955A (enExample)
KR (1) KR20140117644A (enExample)
CN (1) CN104204226A (enExample)
AU (1) AU2013214254B2 (enExample)
BR (1) BR112014019034A8 (enExample)
CA (1) CA2863287A1 (enExample)
IN (1) IN2014DN06127A (enExample)
RU (1) RU2014135224A (enExample)
WO (1) WO2013113796A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109504743A (zh) * 2017-09-13 2019-03-22 复旦大学附属华山医院 阿帕替尼有效生物标志物vegfr-2基因检测试剂盒
JP7734139B2 (ja) * 2020-01-29 2025-09-04 ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム Nrg1融合体を有するがんの治療のためのキナゾリンベースのチロシンキナーゼインヒビターの使用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5559235A (en) 1991-10-29 1996-09-24 Glaxo Wellcome Inc. Water soluble camptothecin derivatives
US5342947A (en) 1992-10-09 1994-08-30 Glaxo Inc. Preparation of water soluble camptothecin derivatives
US5871918A (en) 1996-06-20 1999-02-16 The University Of North Carolina At Chapel Hill Electrochemical detection of nucleic acid hybridization
US5681835A (en) 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
US5491237A (en) 1994-05-03 1996-02-13 Glaxo Wellcome Inc. Intermediates in pharmaceutical camptothecin preparation
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
JP2000508912A (ja) 1996-04-19 2000-07-18 スペクトラ バイオメディカル,インコーポレイテッド 多型形態と複数の表現型との相関付け
AR007857A1 (es) 1996-07-13 1999-11-24 Glaxo Group Ltd Compuestos heterociclicos fusionados como inhibidores de proteina tirosina quinasa, sus metodos de preparacion, intermediarios uso en medicina ycomposiciones farmaceuticas que los contienen.
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
GB9800569D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
PL203326B1 (pl) 1999-06-25 2009-09-30 Genentech Inc Przeciwciało, kompozycja farmaceutyczna, koniugat, izolowany kwas nukleinowy, wektor, komórka gospodarza i sposób wytwarzania przeciwciała
JP4102185B2 (ja) 2000-06-30 2008-06-18 グラクソ グループ リミテッド キナゾリンジトシル酸塩化合物
WO2007095038A2 (en) * 2006-02-09 2007-08-23 Novartis Ag Mutations and polymorphisms of erbb2
US8435752B2 (en) * 2007-01-18 2013-05-07 University Of Southern California Gene polymorphisms predictive for dual TKI therapy
EP2126126A2 (en) * 2007-01-18 2009-12-02 University Of Southern California Gene polymorphisms in vegf and vegf receptor 2 as markers for cancer therapy
EP1980626A1 (en) * 2007-04-13 2008-10-15 Het Nederlands Kanker Instituut Involvement of lipid kinase, and signal transduction pathway comprising said lipid kinase, in resistance to HER2-targeting therapy
WO2008128233A1 (en) * 2007-04-15 2008-10-23 University Of Chicago Methods and compositions concerning the vegfr-2 gene (kinase domain receptor, kdr)
KR101781658B1 (ko) * 2009-08-21 2017-10-23 노파르티스 아게 암의 치료 방법
WO2011060380A1 (en) * 2009-11-14 2011-05-19 The Regents Of The University Of California Pik3ca mutation status and sash1 expression predicts synergy between lapatinib and an akt inhibitor in her2 positive breast cancer

Also Published As

Publication number Publication date
CA2863287A1 (en) 2013-08-08
US20150023953A1 (en) 2015-01-22
AU2013214254A1 (en) 2014-08-14
IN2014DN06127A (enExample) 2015-08-14
KR20140117644A (ko) 2014-10-07
JP2015506955A (ja) 2015-03-05
WO2013113796A1 (en) 2013-08-08
EP3045543A2 (en) 2016-07-20
EP2809805A1 (en) 2014-12-10
AU2013214254B2 (en) 2016-04-21
CN104204226A (zh) 2014-12-10
BR112014019034A2 (enExample) 2017-06-20
RU2014135224A (ru) 2016-03-27
EP3045543A3 (en) 2016-10-12

Similar Documents

Publication Publication Date Title
EA201490891A1 (ru) Пиридопиразины, обладающие противораковой активностью через ингибирование fgfr киназ
CL2014001547A1 (es) Compuestos derivados de benzotienilo-pirrolotriazina, como inhibidores de la proteina tirosina quinasa; procedimiento de preparacion de dichos compuestos; composicion farmaceutica que los comprende; y su uso para el tratamiento y/o la prevencion de cancer y enfermedades tumorales.
MX2020004023A (es) Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia.
JOP20120246B1 (ar) مركبات و تركيبات كمثبطات كيناز c-Kit
EA201591166A1 (ru) Ингибиторы аутотаксина
PH12017501306A1 (en) Inhibitors of histone demethylases
BR112014019052A8 (pt) Inibidores seletivos de cdk8/cdk19 e seu uso em métodos antimetastáticos e quimiopreventivos para câncer
EA201790267A1 (ru) Новые модуляторы киназ
EA201391416A1 (ru) Новые соединения в качестве модуляторов протеинкиназ
EA201291143A1 (ru) Пиразолилхиназолиновые ингибиторы киназы
EA201690495A1 (ru) Меченые ингибиторы простатического специфического мембранного антигена (псма), их применение в качестве агентов для визуализации и фармацевтических агентов для лечения рака предстательной железы
EA201391528A1 (ru) Ингибиторы тирозинкиназы
PE20191655A1 (es) Combinaciones farmaceuticas
AR092899A1 (es) Uso de masitinib para el tratamiento del cancer en subpoblaciones de pacientes identificados que utilizan factores de prediccion
PH12016502353A1 (en) Pharmaceutical composition
BR102012006063A8 (pt) Inibidor de met para uso no tratamento de um paciente sofrendo de um tumor, e, sequência de nucleotídeo
MX369518B (es) Combinacion de inhibidor de p13k e inhibidor de c-met.
TW201613577A (en) Pharmaceutical combinations
MX2016003522A (es) Derivados de quinazolinas y su uso como inhibidores de la adn metiltransferasa.
PH12014502547A1 (en) Dosage regimen for a pi-3 kinase inhibitor
EA201501187A1 (ru) Новые химические соединения (варианты) и их применение для лечения онкологических заболеваний
BR112014018374A8 (pt) Método para predizer a resposta d eum paciente com câncer, kit, anticorpo, método para o tratamento do câncer e composição farmacêutica
MX2016004212A (es) Inhibidor de tor cinasa en la prevencion o tratamiento de cancer caracterizado por mutaciones genicas.
BR112014019034A8 (pt) Método para tratamento de câncer
BR102012028120B8 (pt) Uso de um ou mais derivados de ingenol, composição farmacêutica e medicamento

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2447 DE 28-11-2017 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B25B Requested transfer of rights rejected

Owner name: SMITHKLINE BEECHAM (CORK) LIMITED (IE)